Pure Global

The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naรฏve Subjects With Chronic HCV Genotype 2 Infection - Trial NCT04774107

Access comprehensive clinical trial information for NCT04774107 through Pure Global AI's free database. This Phase 1 trial is sponsored by PharmaEssentia and is currently Recruiting. The study focuses on Hepatitis C, Chronic. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04774107
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT04774107
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naรฏve Subjects With Chronic HCV Genotype 2 Infection
An Open-label Study to Assess the Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naรฏve Subjects With Chronic Hepatitis With HCV Genotype 2 Infection

Study Focus

Hepatitis C, Chronic

P1101 + Ribavirin

Interventional

drug

Sponsor & Location

PharmaEssentia

Chiayi City,Chiayi City,Chiayi City,Kaohsiung City,Kaohsiung,Tainan City,Tainan City,Taitung, Taiwan

Timeline & Enrollment

Phase 1

Nov 26, 2020

Apr 01, 2022

18 participants

Primary Outcome

Amount of P1101 in the blood stream

Summary

Primary Objective:
 
 To determine the P1101 PK profile at the single dose of 400 ฮผg.

ICD-10 Classifications

Chronic viral hepatitis C
Acute hepatitis C
Chronic hepatitis, unspecified
Chronic viral hepatitis
Chronic viral hepatitis, unspecified

Data Source

ClinicalTrials.gov

NCT04774107

Non-Device Trial